GlassScriptPhysician profile
Diane M Scott
NPI 1992786347
$3,232.23
in general payments reported to CMS, 2019-2025
19 companies · $1,682 in 2025
The $1,682 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $121 · 2023: $123 · 2024: $1,305 · 2025: $1,682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,011 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,011.27 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $732.46 | 2023-2025 | Tremfya |
| Hill Dermaceuticals, INC. | $418.05 | 2025 | Tolak |
| Abbvie INC. | $349.18 | 2024-2025 | |
| Pfizer INC. | $284.04 | 2024-2025 | |
| Amgen INC. | $194.92 | 2023-2025 | Otezla, Otezla |
| Incyte Corporation | $158.71 | 2024-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $157.10 | 2024-2025 | Dupixent, Libtayo |
| Arcutis Biotherapeutics, INC. | $127.01 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $120.98 | 2023-2025 | Sotyktu |
| Genzyme Corporation | $120.97 | 2021 | |
| Galderma Laboratories, L.P. | $118.72 | 2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.58 | 2023-2025 | Spevigo, Cyltezo |
| Novartis Pharmaceuticals Corporation | $112.39 | 2024-2025 | |
| Leo Pharma INC. | $55.68 | 2024 | Adbry |
| Sun Pharmaceutical Industries INC. | $51.20 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $50.35 | 2024-2025 | Bimzelx |
| Lilly USA, LLC | $28.82 | 2024 | Ebglyss, Taltz |
| Almirall LLC | $23.11 | 2024 | Klisyri |
| Verrica Pharmaceuticals INC. | $14.96 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.